Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
1st May 2026 Uncategorised 0Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with Alzheimer’s disease.
More: Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
Source: fierce
